Effective delivery of chemotherapeutic nanoparticles by depleting host Kupffer cells

International Journal of Cancer

Volumn 131, Issue 10, 2012, Pages 2402-2410

  Ohara, Yusuke ^a   Oda, Tatsuya ^a   Yamada, Keiichi ^a   Hashimoto, Shinji ^a   Akashi, Yoshimasa ^a   Miyamoto, Ryoichi ^a   Kobayashi, Akihiko ^a   Fukunaga, Kiyoshi ^a   Sasaki, Ryoko ^a   Ohkohchi, Nobuhiro ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Doxil; Kupffer cell; nanoparticles; reticuloendothelial system

Indexed keywords

CLODRONATE LIPOSOME; CLODRONIC ACID; DOXORUBICIN; LIPOSOME; NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DISEASE MODEL; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG LIVER LEVEL; DRUG TUMOR LEVEL; FEMALE; KUPFFER CELL; MACROPHAGE DEPLETION; MOUSE; NANOMEDICINE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROCEDURES CONCERNING CELLS; TUMOR VOLUME;

ANIMALS; CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; KUPFFER CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOCONJUGATES; NEOPLASMS; POLYETHYLENE GLYCOLS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867047472     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27502     Document Type: Article

References (50)

1. Jain RK, Stylianopoulos T,. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010; 7: 653-64.
2. Jamieson T, Bakhshi R, Petrova D, Pocock R, Imani M, Seifalian AM,. Biological applications of quantum dots. Biomaterials 2007; 28: 4717-32.
3. Zhang L, Webster TJ,. Nanotechnology and nanomaterials: Promises for improved tissue regeneration. Nano Today 2009; 4: 66-80.
4. Cho K, Wang X, Nie S, Chen ZG, Shin DM,. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008; 14: 1310-6.
5. Alexis F, Rhee JW, Richie JP, Radovic-Moreno AF, Langer R, Farokhzad OC,. New frontiers in nanotechnology for cancer treatment. Urol Oncol 2008; 26: 74-85.
6. Matsumura Y, Maeda H,. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387-92.
7. Iyer AK, Khaled G, Fang J, Maeda H,. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006; 11: 812-8.
8. Malam Y, Loizidou M, Seifalian AM,. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009; 30: 592-9.
9. Wong HL, Bendayan R, Rauth AM, Xue HY, Babakhanian K, Wu XY,. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J Pharmacol Exp Ther 2006; 317: 1372-81.
10. Green AE, Rose PG,. Pegylated liposomal doxorubicin in ovarian cancer. Int J Nanomedicine 2006; 1: 229-39.
11. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J,. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23: 7794-803.
12. Woodle MC, Lasic DD,. Sterically stabilized liposomes. Biochim Biophys Acta 1992; 1113: 171-99.
13. Storm G, Belliot SO, Daemen T, Lasic DD,. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 1995; 17: 31-48.
14. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R,. Biodegradable long-circulating polymeric nanospheres. Science 1994; 263: 1600-3.
15. Ruoslahti E, Bhatia SN, Sailor MJ,. Targeting of drugs and nanoparticles to tumors. J Cell Biol 2010; 188: 759-68.
16. Moghimi SM, Hunter AC, Murray JC,. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001; 53: 283-318.
17. Owens DE, 3rd, Peppas NA,. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006; 307: 93-102.
18. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C, Martin FJ,. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 1991; 88: 11460-4.
19. Lasic DD,. Doxorubicin in sterically stabilized liposomes. Nature 1996; 380: 561-2.
20. Vaage J, Barbera-Guillem E, Abra R, Huang A, Working P,. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 1994; 73: 1478-84.
21. Soma CE, Dubernet C, Barratt G, Nemati F, Appel M, Benita S, Couvreur P,. Ability of doxorubicin-loaded nanoparticles to overcome multidrug resistance of tumor cells after their capture by macrophages. Pharm Res 1999; 16: 1710-6.
22. Litzinger DC, Buiting AM, van Rooijen N, Huang L,. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim Biophys Acta 1994; 1190: 99-107.
23. Laverman P, Brouwers AH, Dams ET, Oyen WJ, Storm G, van Rooijen N, Corstens FH, Boerman OC,. Preclinical and clinical evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose. J Pharmacol Exp Ther 2000; 293: 996-1001.
24. Laverman P, Carstens MG, Boerman OC, Dams ET, Oyen WJ, van Rooijen N, Corstens FH, Storm G,. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharmacol Exp Ther 2001; 298: 607-12.
25. Laverman P, Boerman OC, Oyen WJG, Corstens FHM, Storm G,. In vivo applications of PEG liposomes: unexpected observations. Crit Rev Ther Drug Carrier Syst 2001; 18: 551-66.
26. Panagi Z, Beletsi A, Evangelatos G, Livaniou E, Ithakissios DS, Avgoustakis K,. Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. Int J Pharm 2001; 221: 143-52.
27. Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG, Stewart JS,. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 2001; 7: 243-54.
28. Moghimi SM, Szebeni J,. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 2003; 42: 463-78.
29. Van Rooijen N, Sanders A,. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 1994; 174: 83-93.
30. Van Rooijen N, Sanders A,. Kupffer cell depletion by liposome-delivered drugs: comparative activity of intracellular clodronate, propamidine, and ethylenediaminetetraacetic acid. Hepatology 1996; 23: 1239-43.
31. Simberg D, Duza T, Park JH, Essler M, Pilch J, Zhang L, Derfus AM, Yang M, Hoffman RM, Bhatia S, Sailor MJ, Ruoslahti E,. Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci USA 2007; 104: 932-6.
32. Wolff G, Worgall S, van Rooijen N, Song WR, Harvey BG, Crystal RG,. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J Virol 1997; 71: 624-9.
33. Hu Q, van Rooijen N, Liu D,. Effect of macrophage elimination using liposome-encapsulated dichloromethylene diphosphonate on tissue distribution of liposomes. J Liposome Res 1996; 6: 681-98.
34. Iwamura T, Katsuki T, Ide K,. Establishment and characterization of a human pancreatic cancer cell line (SUIT-2) producing carcinoembryonic antigen and carbohydrate antigen 19-9. Jpn J Cancer Res 1987; 78: 54-62.
35. Ujiie K, Kanayama N, Asai K, Kishimoto M, Ohara Y, Akashi Y, Yamada K, Hashimoto S, Oda T, Ohkohchi N, Yanagihara H, Kita E, et al. Preparation of highly dispersible and tumor-accumulative, iron oxide nanoparticles Multi-point anchoring of PEG-b-poly (4-vinylbenzylphosphonate) improves performance significantly. Colloids Surf B Biointerfaces 2011; 88: 771-8.
36. Gabizon A, Shiota R, Papahadjopoulos D,. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J Natl Cancer Inst 1989; 81: 1484-8.
37. Gabizon AA,. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res 1992; 52: 891-6.
38. Tsuruta W, Tsurushima H, Yamamoto T, Suzuki K, Yamazaki N, Matsumura A,. Application of liposomes incorporating doxorubicin with sialyl Lewis X to prevent stenosis after rat carotid artery injury. Biomaterials 2009; 30: 118-25.
39. Lloyd CM, Phillips AR, Cooper GJ, Dunbar PR,. Three-colour fluorescence immunohistochemistry reveals the diversity of cells staining for macrophage markers in murine spleen and liver. J Immunol Methods 2008; 334: 70-81.
40. van IMG, de Bruijn EA, ten Hagen TL, de Boeck G, van Eijck CH, Eggermont AM,. Balloon catheter hypoxic abdominal and pelvic perfusion with tumour necrosis factor-alpha, Melphalan and Mitomycin C: a pharmacokinetic study in pigs. Eur J Surg Oncol 2004; 30: 699-707.
41. Vaage J, Donovan D, Mayhew E, Abra R, Huang A,. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer 1993; 72: 3671-5.
42. Fujisaka Y, Horiike A, Shimizu T, Yamamoto N, Yamada Y, Tamura T,. Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors. Jpn J Clin Oncol 2006; 36: 768-74.
43. Gabizon A, Tzemach D, Mak L, Bronstein M, Horowitz AT,. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J Drug Target 2002; 10: 539-48.
44. Arnold RD, Mager DE, Slack JE, Straubinger RM,. Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model. Clin Cancer Res 2005; 11: 8856-65.
45. Daemen T, Hofstede G, Ten Kate MT, Bakker-Woudenberg IA, Scherphof GL,. Liposomal doxorubicin-induced toxicity: depletion and impairment of phagocytic activity of liver macrophages. Int J Cancer 1995; 61: 716-21.
46. Daemen T, Regts J, Meesters M, Ten Kate MT, Bakker-Woudenberg I, Scherphof GL,. Toxicity of doxorubicin entrapped within long-circulating liposomes. J Control Release 1997; 44: 1-9.
47. van Rooijen N, van Kesteren-Hendrikx E,. Clodronate liposomes: perspectives in research and therapeutics. J Liposome Res 2002; 12: 81-94.
48. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ,. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312-22.
49. Lu WL, Qi XR, Zhang Q, Li RY, Wang GL, Zhang RJ, Wei SL,. A pegylated liposomal platform: pharmacokinetics, pharmacodynamics, and toxicity in mice using doxorubicin as a model drug. J Pharmacol Sci 2004; 95: 381-9.
50. Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R,. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation. Health Technol Assess 2006; 10: 1-132 iii-iv.